Physician profile
Anne Mary Leach
NPI 1780661918
$5,501.26
in general payments reported to CMS, 2019-2025
27 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $114 · 2022: $480 · 2023: $1,164 · 2024: $1,347 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,601.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,209.81 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $557.53 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $505.22 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $465.21 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $434.24 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $395.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $331.75 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.53 | 2022-2025 | Caplyta |
| Lundbeck LLC | $219.84 | 2020-2025 | Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $214.72 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $214.03 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $183.37 | 2019-2020 | |
| Indivior INC. | $121.79 | 2019-2025 | Perseris, Sublocade |
| Noven Therapeutics, LLC | $101.03 | 2024-2025 | Secuado, Xelstrym |
| Tris Pharma INC | $35.67 | 2024-2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.27 | 2023-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $34.94 | 2020-2024 | |
| Idorsia Pharmaceuticals US INC | $30.57 | 2023-2024 | Quviviq |
| Allergan, INC. | $29.01 | 2019 | |
| Corium, LLC | $28.49 | 2023-2024 | Azstarys |
| Luye Pharma (USA) LTD. | $24.65 | 2025 | Erzofri Extended-Release |
| Gilead Sciences, INC. | $20.80 | 2025 | |
| Orexo US, INC. | $19.12 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.34 | 2025 | Qelbree |
| Novo Nordisk INC | $15.92 | 2023 | |
| Viiv Healthcare Company | $14.04 | 2025 | Apretude |
| Avanir Pharmaceuticals, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.